NASDAQ · Biotechnology · USD

Eikon Therapeutics, Inc. (EIKN) Stock Analysis

Eikon Therapeutics, Inc. (EIKN) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

EIKN

$10.86

−$0.10 (−0.91%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare EIKN with… →

EIKN Key Statistics

As of Sep 4, 2026

Trading

Open: $10.81
Previous Close: $10.96
Day's Range: 10.62–11.05
52-Week Range: 7.90–17.40
Volume: 238.70K

Valuation

Market Cap: $588.23M
P/E Ratio: unprofitable
EPS (ttm): −5.90

Financials (FY)

Revenue (FY): $0.00
Net Income (FY): −$324.25M
Profit margin: 0.00%
Shares Outstanding: 54.17M

Dividend and dates

Earnings Date: November 12, 2026estimated
Avg Volume: 411.13K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

EIKN Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$0.00	−$324.25M	—
2024	$0.00	−$243.81M	—
2023	$0.00	−$242.00M	—

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$0.00	—	−$338.95M	−$324.25M	—
2024	$0.00	—	−$260.34M	−$243.81M	—
2023	$0.00	—	−$265.74M	−$242.00M	—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

EIKN Valuation vs Biotechnology Median

Median of 656 stocks

Metric	EIKN	Biotechnology median	vs median
Profit margin	0.00%	0.00%	0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Eikon Therapeutics, Inc. (EIKN) is capitalised at $588.23M on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 384 employees.

The 52-week range on file runs from $7.90 to $17.40. EIKN last closed at $10.86 on September 4, 2026. That is −$0.10 (−0.91%) against the previous close. The latest close sits 37.47% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. The same year closed with a net loss of $324.25M. The reported profit margin is 0%. Trailing earnings per share are −5.9.

Across the 3 fiscal years on file, revenue moves from $0.00 in 2023 to $0.00 in 2025. Of those 3 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

The stored price history starts on February 5, 2026, and the total return since then is −27.60%.

Growth & Income

No dividend is on file for EIKN.

2026 is still running; the price is −27.60% year to date.

Peer Comparison

Eikon Therapeutics, Inc. (EIKN) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Eikon Therapeutics, Inc.	EIKN	$588.23M	—
Vertex Pharmaceuticals Incorporated	VRTX	$138.42B	32.5
Regeneron Pharmaceuticals, Inc.	REGN	$85.22B	20.5
argenx SE	ARGX	$64.25B	40.1

The Biotechnology industry average P/E ratio is 12.6x. Eikon Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

ARGX

argenx SE

$64.25B

MRNA

Moderna, Inc.

$58.11B

RVMD

Revolution Medicines, Inc.

$45.01B

ONC

BeOne Medicines AG

$40.53B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

JNJ

Johnson & Johnson

$663.28B

ABBV

AbbVie Inc.

$453.19B

MRK

Merck & Co., Inc.

$370.89B

UNH

UnitedHealth Group Incorporated

$356.47B

View all Healthcare stocks →

About Eikon Therapeutics, Inc.

Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops medicines to address serious unmet medical needs. Its products include EIK1001, a systemically administered TLR 7/8 dual-agonist designed to activate innate and adaptive immune anti-tumor responses; EIK1003 and EIK1004, which are selective PARP1 inhibitors in ovarian, breast, prostate, and pancreatic cancers and, specifically with the brain-penetrant; EIK1004 to address brain metastases and primary brain malignancies; EIK1005, a potent WRN helicase inhibitor and anti-tumor agent for MSI-high tumors; and EIK1006, a clinical candidate and next-generation androgen receptor antagonist with activity against multiple clinically emergent variants of androgen receptor. The company was incorporated in 2019 and is based in Millbrae, California.

Visit website →